CSI Market
Sign In | Register

Aurinia Pharmaceuticals Inc (AUPH) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AUPH quarterly Cash Flow →
The data below summarizes Aurinia Pharmaceuticals Inc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income287.20
Depreciation & amortization0.60
Amortization of Other Assets0.80
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges1.65
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories6.46
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation14.68
Income (Loss) from Equity Method Investments0.00
Adjustments ForFair Value Gains Losses0.00
Adjustments For Increase Decrease In Deferred Income-
Adjustments For Depreciation Expense-
Royalty Obligation Expense-
Increase Decrease In Operating Lease Right Of Use Assets-
Increase Decrease In Contract With Customer Liability3.67
Operating Lease Right Of Use Asset Amortization Expense-
Acquired Upfront License Payment-
Foreign Translation Gain Loss On Revaluation Of Finance Lease Liability9.69
Income taxes-176.19
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables4.91
Increase (Decrease) in Accounts Payable-1.87
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-4.66
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-5.52
Other Working Capital-0.73
Other Noncash Income (Expense)0.20
Other net10.18
Payments for (Proceeds from) Other Operating Activities-10.98
Discontinued operations0.00
Net Cash flow from Operating Activities135.66
Investing Activities
Capital Expenditures0.25
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities494.13
Payments to Acquire Marketable Securities526.65
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Lease Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-32.77
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock98.16
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net9.76
Other net-96.97
Increase Decrease In Cash And Cash Equivalents-
Proceedsfromexerciseofderivativewarrants-
Proceeds From Issuing Other Equity Instruments-
Capital Lease Obligations Incurred-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Finance Lease Principal Payments-13.14
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents83.43
Right Of Use Asset Obtained In Exchange For Finance Lease Liability-
Taxes Withheld Related To Vesting Of Performance Awards3.77
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-106.11
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow135.91
Total Cash Flow-3.22
4 historic quarters locked

Sign in to unlock the full Aurinia Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Aurinia Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: auph-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001600620-26-000017

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License